1. Introduction {#sec1}
===============

Optimization of animal performance is the main goal of modern farming. Until 2006, the use of antibiotic growth promoters (AGP) in the European Union was a key element for improving animal production. Since then, worldwide scientific research has been exploring equally effective alternatives that will maintain animal health, improve animal performance and have no negative impact on animal welfare and consumer health ([@bib47], [@bib18]).

However, the missing knowledge about the exact mechanism of how AGP enhance animal growth ([@bib36]) in combination with the largely unknown complexity of the gastrointestinal ecosystem, makes the development of effective alternatives not straightforward. The ongoing elucidation of the extensive interactions between the poultry host and its gut microbiome such as exchange of nutrients, modulation of host gut morphology, physiology and immunity is required in order to develop future powerful dietary strategies ([@bib6], [@bib41]).

So far, among various substances being researched for their effects on broiler nutrition, organic acids- based formulations (OABF) have received significant attention ([@bib21]). Organic acids have long being utilized in the food industry due to their direct and indirect antimicrobial activity ([@bib54], [@bib30]). Dietary inclusion of an OABF in poultry feed has been shown to modulate gut luminal microbiota composition ([@bib35], [@bib12], [@bib13], [@bib51]). The incorporation of OABF in broiler feed has been shown to exhibit a positive response in performance ([@bib16], [@bib1], [@bib7], [@bib46], [@bib40]), but the exact mechanism behind their growth promoting ability has not been fully elucidated. In addition, direct comparisons of OABF effects as alternatives to AGP are scarce.

From our previous research, it has been shown that inclusion of an OABF consisting of selected organic acids (i.e., formic, propionic and acetic acid) and their salts affected broiler growth performance, nutrient digestibility and energy retention in a beneficial way ([@bib40]). The aim of this work was to generate new knowledge on OABF inclusion effects that could further support zootechnical performance findings by focusing in the study of key gut ecosystem elements. In particular, the study aimed to determine changes in luminal- and mucosa associated bacterial groups, concentration of volatile fatty acids (VFA), activity of microbial glycolytic enzymes and gene expression of several gut barrier and health biomarkers at ileal and cecal level.

2. Materials and methods {#sec2}
========================

2.1. Birds and experimental treatments {#sec2.1}
--------------------------------------

This study forms part of our previous research work ([@bib40]) and in order to avoid excessive repetition, a brief description of the experimental treatments is given below. A total of 544 day-old male Cobb broilers vaccinated for Marek\'s disease, infectious bronchitis and Newcastle disease were acquired from a local hatchery. Birds were arranged according to a 2 × 2 factorial design in 4 treatments, with 8 (*n* = 8) replicate pens of 17 chicks per treatment for a 42-d study. All experimental treatments received a corn-soybean basal diet formulated for starter (1 to 14 d), grower (15 to 28 d) and finisher (29 to 42 d) growth periods. The calculated chemical composition per kg of basal diets were: starter (AME~n~ 12.5 MJ; crude protein 210 g; lysine 12 g; calcium 10 g and available phosphorus 5 g), grower (AME~n~ 12.9 MJ; crude protein 190 g; lysine 11 g; calcium 9.6 g and available phosphorus 4.8 g) and finisher (AME~n~ 13.3 MJ; crude protein 180 g; lysine 10.5 g; calcium 9 g and available phosphorus 4.5 g). Depending on the addition of OABF and/or avilamycin used as a model AGP, experimental treatments were classified as: no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV). There was a coccidiostat addition in the starter and grower basal diets. Diets and water availability were *ad libitum* for the whole experiment. The OABF (Biotronic Top3, Biomin GmbH, Herzogenburg, Austria) consisted of selected organic acids (i.e., formic, propionic and acetic acid) and their salts at 394 g/kg, flavoring components (i.e., cinnamaldehyde and a permeabilizing substance) and carrier.

Birds were reared in an experimental facility designed for broilers and constructed according to the international standards for sterile rooms ISO 14644-1 and F.S. 290E (ClimaThermica Ltd, Athens, Greece) fitted with airlock doors and absolute air filters in all air inlets and outlets. After the trial, all birds were euthanized and incinerated. The experimental protocol was in accordance with the current European Union Directive on the protection of animals used for scientific purposes (EC 43/2007; EU 63/2010) and was approved by the relevant national authority.

2.2. Sampling and processing {#sec2.2}
----------------------------

At the end (42 d) of the experiment, 8 birds per treatment (i.e., one bird/cage) were randomly selected and euthanized, then dissected and relevant samples taken. In particular, broilers were opened, under aseptic conditions and the whole ileum and the 2 ceca were removed. All samples were immediately snap-frozen in liquid nitrogen followed by storage in −80 °C until further analysis.

### 2.2.1. Sample preparation for microbiological analysis {#sec2.2.1}

For the determination of luminal- and mucosa-associated microbiota composition and metabolic activity (i.e., VFA and glycolytic enzymes), a 15-cm segment of broiler ileum and one of the ceca were used.

Ileal and cecal segments were thawed on ice and opened longitudinally. Firstly, digesta content was removed carefully and then in order to remove remaining digesta and bacteria not attached to the gut mucosa, each gut segment was washed 3 times in ice cold saline by gentle agitation. Subsequently, mucosa attached bacteria were removed from the gut mucosa following a protocol of 3 × 1 min vigorous hand shaking washes (15 mL) in saline containing 0.1% (wt/wt) Tween 80, according to [@bib28]. Finally, the washes were pooled and centrifuged at 10,000 × *g* for 30 min at 4 °C to precipitate cells (cell pellet).

### 2.2.2. Sample preparation for gene expression studies {#sec2.2.2}

For the relative expression of mucin 2 (*MUC2*), immunoglobulin A (*IgA*), zonula occludens-1 (*ZO1*), zonula occludens-2 (*ZO2*), claudin-1 (*CLDN1*), claudin-5 (*CLDN5*), occludin (*OCLN*), nuclear factor kappa B subunit 1(*NFKB1*), toll-like receptor 2 family member B (*TLR2B*) and toll-like receptor 4 (*TLR4*), a 10-cm segment of broiler ileum and the second entire cecum were used.

Ileal and cecal segments were thawed on ice and opened longitudinally. Digesta contents were removed carefully and each gut segment was then washed 3 times in ice cold saline by gentle agitation. Subsequently, the cleaned gut mucosa was further washed with ice cold ethylene diamine tetraacetic acid (0.1 mol/L EDTA, pH 7.2). Finally, mucosal scrapings were cautiously obtained with the help of a microscope glass slide.

2.3. DNA extraction {#sec2.3}
-------------------

Ileal, cecal digesta and cell pellets from ileum and caecum were used for DNA extraction using a suitable commercial kit (PSP Spin Stool DNA Kit, Stratec Molecular GmbH, Berlin, Germany). The lysis protocol was optimised by incorporating an additional 30 min lysozyme and a 15 min RNase digestion step. For each sample, the purified DNA was eluted in 200 μL elution buffer and the quality and quantity of the preparations were determined by spectrophotometry (NanoDrop-1000, Thermo Fisher Scientific, Waltham, UK) and stored at −30 °C.

2.4. Quantitative real time PCR {#sec2.4}
-------------------------------

To quantify total bacteria (domain bacteria), *Lactobacillus* spp*., Escherichia coli, Bifidobacterium* spp*., Bacteroides* spp*., Clostridium perfringens* subgroup (*Clostridium* cluster I)*, Clostridium leptum* subgroup (*Clostridium* cluster IV) and *Clostridium coccoides* subgroup (*Clostridium* cluster XIVa), suitable primers were used targeting the 16S rRNA gene ([Table 1](#tbl1){ref-type="table"}). Primer specificity was confirmed using BLAST (NCBI) and PROBE MATCH program (Ribosomal Database Project II; [@bib9]).Table 1Primers targeting 16S rRNA gene used for determination of luminal- and mucosa-associated microbiota composition by real time PCR.Target group or organismSequence (5′ to 3′)Annealing temperature, °CReferenceAll bacteria\
(domain bacteria)F: ACTCCTACGGGAGGCAGCAG\
R: ATTACCGCGGCTGCTGG60[@bib8]*Bacteroides* spp.F: GAGAGGAAGGTCCCCCAC\
R: CGCTACTTGGCTGGTTCAG58[@bib43]*Lactobacillus* spp.F: GAGGCAGCAGTAGGGAATCTTC\
R:GGCCAGTTACTACCTCTATCCTTCTTC60[@bib14];\
[@bib43]*Bifidobacterium* spp.F: CGCGTCYGGTGTGAAAG\
R: CCCCACATCCAGCATCCA58[@bib14];\
[@bib43]*Escherichia coli*F: CATGCCGCGTGTATGAAGAA\
R:GGGTAACGTCAATGAGCAAAGG60[@bib48]*Clostridium perfringens* subgroup\
(*Clostridium* cluster I)F: TACCHRAGGAGGAAGCCAC\
R:GTTCTTCCTAATCTCTACGCAT56[@bib18]*Clostridium leptum* subgroup\
(*Clostridium* cluster IV)F: GCACAAGCAGTGGAGT\
R: CTTCCTCCGTTTTGTCAA52[@bib32]*Clostridium coccoides* subgroup\
(*Clostridium* cluster XIVa)F: ACTCCTACGGGAGGCAGC\
R:CTTCTTAGTCAGGTACCGTCAT60[@bib52]

Real time PCR was performed in microplates with the Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Reactions were made at a 15 μL final volume and consisted of a 7.5 μL 2 × Green Dye master mix (Rovalab GmbH, Teltow, Germany), forward and reverse primers each at final concentration of 300 to 450 nmol/L, 0.75 μL of bovine serum albumin (20 μg/mL), 0.15 μL passive ROX reference dye (50 nmol/L final concentration) and 2 μL of DNA template (20 ng sample DNA/reaction). The reactions were incubated at 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, primer specific annealing temperature for 60 s, then 72 °C for 60 s. Target amplification was followed by a melt curve analysis to determine the reaction specificity. Each sample was measured in duplicates. Depending on whether the sample was from mucosa or luminal digesta, results were expressed as log cells/g mucosa-associated cell pellet or as log cells/g wet digesta contents, respectively.

2.5. Bacterial strains and calibration curves {#sec2.5}
---------------------------------------------

Reference bacterial strains that were used to control the specificity of the primers and to construct standard curves are shown on [Table 2](#tbl2){ref-type="table"}. Each of the reference strains was cultured on selective broth under suitable conditions. Bacterial genomic DNA from each culture was extracted using PSP Spin Stool DNA Kit (Stratec Molecular GmbH, Berlin, Germany).Table 2Reference strains and genome sizes.Reference strainsTarget bacterial group(s)NCBI reference sequenceGenome size, Mbp*Escherichia coli* ATCC 25922*Escherichia* sp. & domain bacteriaNZ_CP009072.15.13*Bacteroides vulgatus* ATCC 8482*Bacteroides* spp.NC_009614.15.16*Lactobacillus acidophilus* ATCC 314*Lactobacillus* spp.NC_006814.31.99*Bifidobacterium animalis* subsp. *animalis* ATCC 25527*Bifidobacterium* spp.NC_017834.11.93*Clostridium perfringens* ATCC 13124*C. perfringens* subgroup\
(*Clostridium* cluster I)NC_008261.13.26*Clostridium leptum* DSM 753*C. leptum* subgroup (*Clostridium* cluster IV)NZ_ABCB00000000.23.27*Clostridium clostridioforme* DSM933*C. coccoides* subgroup (*Clostridium* cluster XIVa)NZ_FOOJ00000000.15.47

For the quantification of bacterial species and groups, a quantification method similar to the one described by [@bib22] was used. In more detail, an appropriate standard curve using 10-fold serial dilutions of known concentration of genomic DNA was included on each 96-well plate. The number of genome copies, from each bacterial species in the initial purified DNA solution used to construct the standard curves, was calculated by assuming an average molecular mass of 660 Da for 1 bp of double-stranded DNA and using the following equation: Number of genome copies = Quantity of DNA (fg)/Mean mass of the corresponding genome (fg). The number of genome copies corresponds to an equal amount of bacterial cells. Genome sizes for all bacteria species and groups used in this study are presented in [Table 2](#tbl2){ref-type="table"}.

2.6. RNA isolation and reverse transcription to cDNA {#sec2.6}
----------------------------------------------------

Extraction of total RNA from ileal and cecal mucosal scrapings was performed using Trifast Reagent (PEQLAB Biotechnologie GmbH, Erlangen, Germany) according to the manufacturer\'s protocol. RNA quantity was determined by spectrophotometry (NanoDrop-1000, Thermo Fisher Scientific, Waltham, UK). Prior to cDNA synthesis, DNAse treatment was applied. Ten μg of RNA were treated with 1 U of DNase I (M0303, New England Biolabs Inc., Ipswich, UK) and 10 μL of DNAse buffer (10 × ) for 1 h at 37 °C. The DNAse was inactivated by the addition of 1 μL of 0.5 mol/L EDTA at 75 °C for 10 min. RNA integrity was assessed by agarose gel electrophoresis.

For cDNA preparation, 500 ng of total RNA from each sample were reverse transcribed to cDNA by PrimeScript RT Reagent Kit (Perfect Real Time, Takara Bio Inc., Shiga, Japan) according to the manufacturer\'s recommendations. cDNAs were stored at −20 °C.

2.7. Quantitative polymerase chain reaction (qPCR) {#sec2.7}
--------------------------------------------------

The ileal and cecal mRNA expression of *MUC2* and *IgA*, *TLR2* and *TLR4*, intestinal tight junctions (*CLDN1*, *CLDN2*, *CLDN5* and *OCLN*) and *NFKB1* were detected using quantitative real time PCR SaCycler-96 (Sacace Biotechnologies Srl) with KAPA SYBR Fast qPCR Kits (KAPA Biosystems, Wilmington, MA, USA). The primer sequences used for real-time PCR are listed in [Table 3](#tbl3){ref-type="table"}. Primers not originating from scientific literature were designed with the PerlPrimer program v.1.1.19 ([@bib31]) using the GenBank sequences. Primer specificity and efficiency were determined by using pooled samples.Table 3Oligonucleotide primers used for quantitative RT-PCR.TargetPrimer sequence (5′ to 3′)Annealing temperature, °CPCR product size, bpGenBank accession No.*GAPDH*F: GCTGAATGGGAAGCTTACTG\
R: AAGGTGGAGGAATGGCTG60216[NM_204305.1](ncbi-n:NM_204305.1){#intref0010}*MUC2*F:TCACCCTGCATGGATACTTGCTCA\
R:TGTCCATCTGCCTGAATCACAGGT62228[NM_001318434.1](ncbi-n:NM_001318434.1){#intref0015}*IgA*F:GTCACCGTCACCTGGACTACA\
R:ACCGATGGTCTCCTTCACATC60192[S40610](ncbi-n:S40610){#intref0020}*ZO1*F:TAAAGCCATTCCTGTAAGCC\
R:GTTTCACCTTTCTCTTTGTCC60243[XM_015278975.1](ncbi-n:XM_015278975.1){#intref0025}*ZO2*F:GTTTCACCTTTCTCTTTGTCC\
R:TAAAGCCATTCCTGTAAGCC60239[NM_204918.1](ncbi-n:NM_204918.1){#intref0030}*CLDN1*F:CTGATTGCTTCCAACCAG\
R:CAGGTCAAACAGAGGTACAAG59140[NM_001013611.2](ncbi-n:NM_001013611.2){#intref0035}*CLDN5*F:CATCACTTCTCCTTCGTCAGC\
R:GCACAAAGATCTCCCAGGTC59111[NM_204201.1](ncbi-n:NM_204201.1){#intref0040}*OCLN*F:TCATCGCCTCCATCGTCTAC\
R:TCTTACTGCGCGTCTTCTGG62240[NM_205128.1](ncbi-n:NM_205128.1){#intref0045}*NFKB1*F: TGTGGTTGTCAGGATGGTC\
R: GGTCTGGTAAAGGTCATTTCTC62273[NM_205134](ncbi-n:NM_205134){#intref0050}*TLR2B*F:CTTGGAGATCAGAGTTTGGA\
R:ATTTGGGAATTTGAGTGCTG62238[NM_001161650.1](ncbi-n:NM_001161650.1){#intref0055}*TLR4*F: GTCTCTCCTTCCTTACCTGCTGTTC\
R:AGGAGGAGAAAGACAGGGTAGGTG65187[NM_001030693.1](ncbi-n:NM_001030693.1){#intref0060}[^1]

Each reaction contained 5 ng RNA equivalents as well as 200 to 300 nmol/L of forward and reverse primers for each gene. The reactions were incubated at 95 °C for 3 min, followed by 40 cycles of 95 °C for 5 s, 59 or 60 or 62 °C (depends on the target gene) for 20 s, 72 °C for 33 s. This was followed by a melt curve analysis to determine the reaction specificity. Each sample was measured in duplicates. Relative expression ratios of target genes were calculated according to [@bib42] using glyceraldehyde 3 phophate dehydrogenase (*GAPDH*) as a reference gene.

2.8. Digesta volatile fatty acid concentration {#sec2.8}
----------------------------------------------

For the determination of ileal or cecal VFA concentration, digesta were homogenized following a 10-fold dilution (i.e., 10% wt/vol) in sterile ice-cold phosphate buffered saline (0.1 mol/L, pH 7.0). Digesta homogenates were subsequently centrifuged 12,000 × *g* for 10 min at 4 °C and the resulting supernatants were stored at −80 °C until their analysis by capillary gas chromatography (GC) using an Agilent 6890 GC System, equipped with a 30 m × 0.25 mm i.d. Nukol column (Supelco, Sigma-Adrich, St Louis, MO, USA) and a flame ionisation detector (FID). The analysis was isothermal (185 °C) and the temperatures of the injector and FID were set at 185 and 200 °C, respectively, as previously described ([@bib34]).

The VFA determined were acetic, propionic, isobutyric, butyric, isovaleric, valeric, isohexanoic, hexanoic and heptanoic acids. Results were expressed as mmol/kg wet digesta for total VFA and as molar ratios (% of total VFA) for acetic, propionic, butyric, branched VFA (b-VFA; sum of isobutyric, isovaleric and isohexanoic acids) and other VFA (o-VFA; sum of valeric, hexanoic and heptanoic acids).

2.9. Digesta activity of microbial glycolytic enzymes {#sec2.9}
-----------------------------------------------------

Microbial glycolytic activities of α-glucosidase, β-glucosidase, β-galactosidase and β-glucuronidase enzymes were determined through the rate of release of p-nitrophenol (pNP) from the respective p-nitrophenylglucoside substrates namely α-glucoside (1 mmol/L), β-glucoside (1 mmol/L), β-galactoside (2 mmol/L) and β-glucuronide (1 mmol/L) according to [@bib33]. Briefly, 1 volume of diluted digesta supernatants (see above) in sterile ice-cold PBS was reacted with 4 volumes (1:4) of the appropriate p-nitrophenylglucoside substrate prepared in sterile PBS (0.1 mol/L, pH 7.0) that had been pre-equilibrated to the reaction temperature. The reaction time was 25 min at 37 °C. The reaction was stopped by the addition of 10 volumes of ice-cold Na~2~CO~3~ (1 mol/L) and absorbance measured at 405 nm. All enzyme activities were calculated using a standard curve for pNP and were expressed as μmol of pNP released per minute per digesta soluble protein.

2.10. Statistical analysis {#sec2.10}
--------------------------

Experimental data on luminal- and mucosa-associated microbiota, microbial glycolytic enzyme activity, VFA and the relative quantification of genes of interest were based on individual broilers. All data were tested for normality using the Kolmogorov--Smirnov test and found to be normally distributed. Subsequently, data were analyzed with the general linear model (GLM) -- general factorial ANOVA procedure using OABF (No/Yes) and avilamycin (No/Yes) as fixed factors. Probability values of equal or less than 0.05 (*P* ≤ 0.05) were considered significant. Statistical significant effects were further analyzed and treatment means were compared using Tukey HSD test using the SPSS for Windows statistical package program, version 8.0.0 (SPSS, Chicago, IL, USA).

3. Results {#sec3}
==========

3.1. Microbiota composition {#sec3.1}
---------------------------

### 3.1.1. Ileum {#sec3.1.1}

The inclusion of OABF or avilamycin had no impact (*P* \> 0.05) on the concentration of total bacteria, *Bacteroides* spp., *Lactobacillus* spp., *E. coli*, *C. leptum* subgroup and *C. coccoides* subgroup in the ileal contents ([Table 4](#tbl4){ref-type="table"}). However, the concentration of *C. perfringens* subgroup in the ileum was significantly decreased (*P*~A~ = 0.045) by avilamycin inclusion.Table 4Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin on ileal digesta microbiota (log cells/g wet digesta content) of 42-day-old broilers.ItemTotal bacteria*Bacteroides* spp.*Lactobacillus* spp.*Escherichia coliClostridium perfringens*\
subgroup*Clostridium leptum* subgroup*Clostridium coccoides* subgroupMain effectOABF[1](#tbl4fn1){ref-type="table-fn"}No8.125.767.435.906.425.446.71Yes8.135.927.466.106.685.486.94Avilamycin[2](#tbl4fn2){ref-type="table-fn"}No8.115.987.586.236.885.526.88Yes8.145.697.305.776.225.416.77Treatments[3](#tbl4fn3){ref-type="table-fn"}CON8.055.847.476.216.855.456.88OA8.176.127.706.256.905.586.88OAAV8.095.727.225.956.455.387.00AV8.195.677.385.585.985.446.54StatisticsSEM[4](#tbl4fn4){ref-type="table-fn"}0.1160.2590.2420.2870.3140.1380.132*P*~O~0.9580.5380.8940.4910.4210.7590.095*P*~A~0.8270.2710.2580.1160.0450.4400.414*P*~O*×*A~0.3630.6680.4290.5630.5090.4830.099[^2][^3][^4][^5]

A significant OABF × avilamycin interaction (*P*~O ×\ A~ = 0.028) was noted for the concentration of ileal mucosa-associated total bacteria. In particular, total bacteria counts were lower in OAAV compared with AV ([Table 5](#tbl5){ref-type="table"}).Table 5Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on ileal mucosa-associated bacteria (log cells/g mucosa-associated cell pellet) of 42-day-old broilers.ItemTotal bacteria*Lactobacillus* spp.*Clostridium coccoides* subgroupMain effectOABF [1](#tbl5fn1){ref-type="table-fn"}No7.195.816.09Yes7.095.756.07Avilamycin[2](#tbl5fn2){ref-type="table-fn"}No7.145.856.15Yes7.145.726.00Treatments[3](#tbl5fn3){ref-type="table-fn"}CON7.07^ab^5.735.96OA7.22^ab^5.966.34OAAV6.97^b^5.545.79AV7.31^a^5.906.21StatisticsSEM[4](#tbl5fn4){ref-type="table-fn"}0.1060.1840.233*P*~O~0.3680.7310.931*P*~A~0.9560.4850.525*P*~O*×*A~0.0280.1240.096[^6][^7][^8][^9][^10]

### 3.1.2. Cecum {#sec3.1.2}

Inclusion of OABF resulted in significantly increased levels of *C. leptum* subgroup and *C. coccoides* subgroup (*P*~O~ = 0.018, *P*~O~ = 0.040, respectively) in the cecal digesta ([Table 6](#tbl6){ref-type="table"}). In contrast, avilamycin did not affect (*P* \> 0.05) any of the determined microbiota components. In addition, cecal mucosa-associated bacterial populations were not affected (*P* \> 0.05) by OABF or avilamycin inclusion ([Table 7](#tbl7){ref-type="table"}).Table 6Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on cecal digesta microbiota (log cells/g wet digesta content) of 42-day-old broilers.ItemTotal bacteria*Bacteroides* spp.*Lactobacillus* spp.*Bifidobacterium* spp.*Escherichia coliClostridium perfringens* subgroup*Clostridium leptum*\
subgroup*Clostridium coccoides*\
subgroupMain effectOABF[1](#tbl6fn1){ref-type="table-fn"}No10.129.527.085.377.137.039.289.25Yes10.209.617.175.267.167.329.479.40Avilamycin[2](#tbl6fn2){ref-type="table-fn"}No10.169.577.145.467.027.159.369.32Yes10.169.567.115.187.287.209.389.33Treatments [3](#tbl6fn3){ref-type="table-fn"}CON10.079.477.015.507.036.979.249.18OA10.259.677.275.417.007.329.499.46OAAV10.149.557.075.117.327.329.459.34AV10.179.567.155.247.237.089.319.32StatisticsSEM[4](#tbl6fn4){ref-type="table-fn"}0.0670.0840.2440.2580.1730.1970.0770.070PO0.2700.2780.7110.6540.8540.1430.0180.040PA0.9430.8750.9040.2910.1470.7730.8310.886*P*~O*×*A~0.1270.2130.5020.9400.7260.7560.4370.071[^11][^12][^13][^14]Table 7Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on cecal mucosa-associated bacteria (log cells/g mucosa-associated cell pellet) of 42-day-old broilers.itemTotal bacteria*Bacteroides* spp.*Lactobacillus* spp.*Clostridium leptum* subgroup*Clostridium coccoides* subgroupMain effectOABF[1](#tbl7fn1){ref-type="table-fn"}No8.567.988.028.027.76Yes8.598.008.118.117.72Avilamycin[2](#tbl7fn2){ref-type="table-fn"}No8.527.947.967.967.65Yes8.638.048.168.167.82Treatments [3](#tbl7fn3){ref-type="table-fn"}CON8.557.957.987.987.76OA8.497.927.957.957.56OAAV8.708.088.278.277.88AV8.578.008.058.057.77StatisticsSEM[4](#tbl7fn4){ref-type="table-fn"}0.1580.1690.2290.1610.148*P*~O~0.8280.9020.5780.5790.787*P*~A~0.4690.5450.8420.2280.263*P*~O*×*A~0.5740.7540.6990.4350.319[^15][^16][^17][^18]

3.2. Microbial glycolytic activity {#sec3.2}
----------------------------------

### 3.2.1. Ileum {#sec3.2.1}

The inclusion of OABF resulted in increased activities of α-glucosidase (*P*~O~ = 0.028), β-glucosidase (*P*~O~ = 0.014), α-galactosidase (*P*~O~ = 0.021) and β-glucuronidase (*P*~O~ = 0.005) in ileal digesta ([Table 8](#tbl8){ref-type="table"}). Avilamycin inclusion did not affect any of the microbial glycolytic activities examined.Table 8Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on microbial glycolytic enzyme activity (μmol p-nitrophenol released/min per g digesta soluble protein) at ileal digesta of 42-day-old broilers.Itemα-glucosidaseβ-glucosidaseα-galactosidaseβ-galactosidaseβ-glucuronidaseMain effectOABF[1](#tbl8fn1){ref-type="table-fn"}No22.4316.7224.5522.3417.99Yes26.9521.3233.6130.6824.44Avilamycin[2](#tbl8fn2){ref-type="table-fn"}No25.9719.8629.5424.8421.12Yes23.4118.1728.6228.1821.31Treatments[3](#tbl8fn3){ref-type="table-fn"}CON23.4117.0824.6421.2417.42OA28.5322.6434.4528.4324.81OAAV25.3720.0032.7732.9324.06AV21.4616.3524.4723.4318.55StatisticsSEM[4](#tbl8fn4){ref-type="table-fn"}1.9501.7543.7134.2882.124*P*~O~0.0280.0140.0210.0620.005*P*~A~0.2010.3440.8060.4420.929*P*~O*×*A~0.7580.5900.8410.7890.663[^19][^20][^21][^22]

### 3.2.2. Caecum {#sec3.2.2}

In the cecal digesta, except for β-galactosidase that was significantly decreased (*P*~A~ = 0.031) by avilamycin addition, no other changes regarding the microbial glycolytic activities were seen ([Table 9](#tbl9){ref-type="table"}).Table 9Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on microbial glycolytic enzyme activity (μmol p-nitrophenol released/min per g digesta soluble protein) at cecal digesta of 42-day-old broilers.Itemα-glucosidaseβ-glucosidaseα-galactosidaseβ-galactosidaseβ-glucuronidaseMain effectOABF[1](#tbl9fn1){ref-type="table-fn"}No58.8136.0838.6586.6376.92Yes59.6835.8340.8866.5078.38Avilamycin[2](#tbl9fn2){ref-type="table-fn"}No63.3338.8943.1299.2578.17Yes55.1733.0336.4153.8977.13Treatments[3](#tbl9fn3){ref-type="table-fn"}CON56.9834.6436.88112.0075.36OA69.6743.1349.3786.4980.97OAAV49.6828.5332.4046.5175.78AV60.6537.5340.4161.2678.48StatisticsSEM[4](#tbl9fn4){ref-type="table-fn"}6.7005.2485.35219.91311.878*P*~O~0.8990.9620.6790.3210.903*P*~A~0.2330.2740.2200.0310.931*P*~O*×*A~0.0880.1070.0660.7890.729[^23][^24][^25][^26]

3.3. Volatile fatty acid concentration {#sec3.3}
--------------------------------------

### 3.3.1. Ileum {#sec3.3.1}

Total VFA concentration in the ileal digesta was not affected by OABF or avilamycin addition ([Table 10](#tbl10){ref-type="table"}). Regarding the molar ratios of individual VFA, avilamycin had an effect on acetic acid and butyric acid. In particular, avilamycin inclusion resulted in a lower molar ratio of acetic acid (*P*~A~ = 0.021) and a higher molar ratio of butyric acid (*P*~A~ = 0.010) compared with the non-avilamycin supplemented treatments.Table 10Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on the volatile fatty acid (VFA) concentration and molar ratios in the ileal digesta of 42-day-old broilers.ItemTotal VFA[1](#tbl10fn1){ref-type="table-fn"}, mmol/kg of wet ileal digestaAcetic, %Propionic, %Butyric, %Other VFA[2](#tbl10fn2){ref-type="table-fn"}, %Branched VFA[3](#tbl10fn3){ref-type="table-fn"}, %Main effectOABF[4](#tbl10fn4){ref-type="table-fn"}No8.1769.883.9115.236.384.62Yes9.0573.653.6212.465.594.68Avilamycin[5](#tbl10fn5){ref-type="table-fn"}No8.6375.633.4911.175.743.98Yes8.5967.914.0416.526.235.32Treatments[6](#tbl10fn6){ref-type="table-fn"}CON7.7973.613.6012.346.513.94OA9.4877.643.3810.004.964.03OAAV8.6369.663.8614.936.235.34AV8.5566.154.2118.116.245.30StatisticsSEM[7](#tbl10fn7){ref-type="table-fn"}0.8003.1600.5111.9400.7140.731*P*~O~0.2800.2430.5780.1660.2830.932*P*~A~0.9570.0210.2910.0100.4950.078*P*~O*×*A~0.3220.9360.9040.8280.2910.973[^27][^28][^29][^30][^31][^32][^33]

### 3.3.2. Caecum {#sec3.3.2}

From the VFA determined in the cecal digesta, inclusion of avilamycin significantly increased (*P*~A~ = 0.043) the molar ratio of o-VFA ([Table 11](#tbl11){ref-type="table"}). There were no other VFA changes by neither OABF nor avilamycin inclusion.Table 11Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on the volatile fatty acid (VFA) concentration and molar ratios in the cecal digesta of 42-day-old broilers.ItemTotal VFA[1](#tbl11fn1){ref-type="table-fn"}, mmol/kg of wet\
cecal digestaAcetic, %Propionic, %Butyric, %Other VFA[2](#tbl11fn2){ref-type="table-fn"}, %Branched VFA[3](#tbl11fn3){ref-type="table-fn"}, %Main effectOABF[4](#tbl11fn4){ref-type="table-fn"}No112.4462.239.2823.502.042.94Yes102.3662.259.0823.132.323.21Avilamycin[5](#tbl11fn5){ref-type="table-fn"}No112.4162.049.7323.082.043.09Yes102.3962.448.6423.542.333.06Treatments[6](#tbl11fn6){ref-type="table-fn"}CON110.8063.039.0922.662.033.19OA114.0161.0610.3623.502.053.00OAAV90.7063.447.8022.752.593.43AV114.0961.449.4824.342.062.70StatisticsSEM[7](#tbl11fn7){ref-type="table-fn"}9.4671.2470.7831.8700.1360.406*P*~O~0.2960.9880.8000.8430.0520.513*P*~A~0.2990.7550.1760.8060.0430.939*P*~O*×*A~0.1710.1230.0700.5220.0760.270[^34][^35][^36][^37][^38][^39][^40]

3.4. Gene expression of intestinal mucosal barrier proteins {#sec3.4}
-----------------------------------------------------------

### 3.4.1. Ileum {#sec3.4.1}

Gene expression of *MUC2, IgA, ZO1, ZO2, CLDN1, CLDN5, OCLN, NFKB1, TLR2b* and *TLR4* results are shown in [Table 12](#tbl12){ref-type="table"}. Regarding factor main effects, supplementation with OABF significantly decreased the expression of *MUC2* (*P*~O~ = 0.027), *ZO1* (*P*~O~ = 0.016) and *CLDN5* (*P*~O~ = 0.003), whereas avilamycin inclusion significantly decreased the expression levels of *ZO1, CLDN5, OCLN, NFKB1, TLR2B* and *TLR4* (*P*~A~ = 0.016, *P*~A~ = 0.001, *P*~A~ = 0.018, *P*~A~ = 0.024, *P*~A~ = 0.011 and *P*~A~ = 0.014, respectively).Table 12Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on relative mRNA levels of ileal mucosa barrier genes of 42-day-old broilers.Item*MUC2IgAZO1ZO2CLDN1CLDN5OCLNNFKB1TLR2BTLR4*Main effectOABF[1](#tbl12fn1){ref-type="table-fn"}No1.1962.9251.891.521.321.791.521.231.972.07Yes0.8513.4261.001.101.380.830.991.241.471.16Avilamycin[2](#tbl12fn2){ref-type="table-fn"}No1.0193.4121.881.421.641.861.601.552.492.25Yes1.0282.9381.011.201.050.770.910.920.960.97Treatments[3](#tbl12fn3){ref-type="table-fn"}CON1.0493.7532.82^a^2.03^a^2.06^a^2.67^a^2.141.743.063.11OA0.9883.0720.94^b^0.81^b^1.23^ab^1.04^b^1.071.351.921.39OAAV0.7143.7801.07^b^1.40^ab^1.53^ab^0.62^b^0.911.121.020.92AV1.3432.0960.95^b^1.02^b^0.57^b^0.92^b^0.900.720.891.02StatisticsSEM[4](#tbl12fn4){ref-type="table-fn"}0.1480.7700.3440.3410.3340.3310.2950.2620.5650.490*P*~O~0.0270.5200.0160.2280.8590.0030.1690.9740.3810.073*P*~A~0.9470.5430.0160.5330.0850.0010.0180.0240.0110.014*P*~O*×*A~0.0650.1360.0070.0270.0120.0360.1250.1400.2720.110[^41][^42][^43][^44][^45][^46]

In addition, significant OABF × avilamycin interactions were noted for the expression of *ZO1* (*P*~O~ ~×\ A~ = 0.007), *ZO2* (*P*~O~ ~×\ A~ = 0.027), *CLDN1* (*P*~O~ ~×\ A~ = 0.012), and *CLDN5* (*P*~O~ ~×\ A~ = 0.036). In particular, broilers in CON showed the highest *ZO1* expression compared with those in the other 3 treatments. In addition, the expression of *ZO2* was higher in CON than in OA and AV, with OAAV being intermediate. Furthermore, *CLDN1* expression was higher in CON than in AV, whereas OAAV and OA were intermediate. Moreover, OAAV, AV and OA had lower *CLDN5* expression than CON.

### 3.4.2. Cecum {#sec3.4.2}

From the genes studied, OABF up-regulated the relative expression of *MUC2* (*P*~O~ = 0.014), whereas, avilamycin addition significantly down-regulated (*P*~A~ = 0.044) *IgA* ([Table 13](#tbl13){ref-type="table"}).Table 13Effect of dietary inclusion of an organic acids-based formulation (OABF) and avilamycin dietary inclusion on relative mRNA levels of cecal mucosa barrier genes of 42-day-old broilers.Item*MUC2IgAZO1ZO2CLDN1CLDN5OCLNNFKB1TLR2BTLR4*Main effectOABF[1](#tbl13fn1){ref-type="table-fn"}No0.7521.0691.241.201.291.071.291.111.171.03Yes1.1360.9331.321.051.221.311.271.481.461.48Avilamycin[2](#tbl13fn2){ref-type="table-fn"}No0.9741.1541.111.091.231.071.021.281.291.11Yes0.9140.8481.451.161.271.301.531.311.351.40Treatments[3](#tbl13fn3){ref-type="table-fn"}CON0.6961.530^a^1.121.321.320.861.271.341.000.72OA1.2510.778^bc^1.100.851.141.290.791.211.581.49OAAV1.0211.089^b^1.551.241.291.331.741.741.341.47AV0.8070.608^c^1.351.071.261.271.310.871.351.33StatisticsSEM[4](#tbl13fn4){ref-type="table-fn"}0.1460.1450.3380.2220.3190.2790.3780.3220.3460.309*P*~O~0.0140.3580.7950.5090.8130.3910.8520.2590.4110.157*P*~A~0.6850.0440.3270.7510.8830.4170.1540.9310.8660.350*P*~O~ ~× A~0.252\<0.0010.7360.1610.7450.5220.2110.1300.4010.323[^47][^48][^49][^50][^51][^52]

In addition, an OABF × avilamycin interaction was noted for the relative expression of *IgA* (*P*~O ×\ A~ \< 0.001). In particular, the highest IgA expression was noted for broilers of treatment CON and the lowest for broilers of treatment AV with treatments OA and OAAV being intermediate.

4. Discussion {#sec4}
=============

It is generally accepted that gut microbiota contributes significantly to the intestinal function and thus has significant impact on the growth and health of chickens ([@bib17]). The vast majority of gut bacteria resides in the distal intestine, particularly in the ceca, which are mainly colonized by obligate anaerobes ([@bib37], [@bib3]).

In this study, real time PCR was used to determine the effect of dietary inclusion of an OABF and/or avilamycin used as an AGP model for comparison on selected dominant commensal microbiota constituents in broiler ileal and cecal mucosa as well as luminal digesta. In particular, at the ileal level, treatment OAAV resulted in lower total mucosal-associated bacterial levels compared with treatment AV. On the other hand, avilamycin reduced ileal digesta *C. perfringens* counts. Moreover, avilamycin is known to display bactericidal activity against Gram-positive bacteria ([@bib26]) such as *C. perfringens* ([@bib25], [@bib53]) and therefore its inclusion as a positive control in this study could explain the reduced ileal digesta counts of *C. perfringens*. Generally, organic acids have been shown to possess antimicrobial properties ([@bib54], [@bib30]) that may affect ileal lactic acid bacteria and *E. coli* ([@bib44], [@bib35], [@bib20], [@bib51]) and this could partly explain the reduction in the overall population of ileal mucosa-associated bacteria in this study.

The limited organic acids effects on ileal microbiota composition could be associated with the negligible changes on ileal VFA concentration and profile. However, the activities of microbial glycolytic enzymes determined in ileal digesta were significantly increased by OABF. This fact may imply metabolic stimulation of ileal microbiota, for example of α-glucosidase, β-glucosidase and α-galactosidase, could point to an increased overall digestive capacity for starch, non-starch polysaccharides and dietary α-galactosides (e.g., rafinose and stachyose), respectively ([@bib33]). The aforementioned improved digestive capacity could have had a positive effect on the overall nutrient digestibility, energy salvage and broiler performance reported by [@bib40].

At the cecal level, OABF and/or avilamycin inclusion had no effect on the mucosa-associated microbiota constituents examined. However, cecal digesta *C. coccoides* subgroup and *C. leptum* subgroup levels were significantly increased by dietary OABF inclusion by 0.15 log and 0.19 log, respectively, compared with that in the non-OABF supplemented birds. Effects of organic acids on cecal microbiota members such as total bacteria and *Salmonella* have been also reported by other studies ([@bib19], [@bib15]). The noted increases in *C. coccoides* subgroup and *C. leptum* subgroup, also known as *Clostridium* XIVa and *Clostridium* IV clusters, although were low, they could be regarded as important and beneficial for gut health. These clusters are among the most abundant cecal digesta bacteria ([@bib17]) including a large number of butyrate producers that are valuable for gut homeostasis ([@bib29]).

Unlike in the ileum, the changes in cecal microbiota composition were not associated with significant changes in microbial metabolic activity. This could in part be attributed to the highly digestible diets used in this study, which is in contrast with other studies where the presence of non-digestible carbohydrates in broiler ceca yielded differences in VFA profile and concentration ([@bib23], [@bib24]). As it was expected, the total VFA concentration was lower in the ileum than in the ceca since bacterial fermentation is limited in the small intestine of broilers due to the short digesta transit time ([@bib45]).

In the present study, OABF inclusion resulted in downregulation of expression of genes encoding tight junction proteins (*ZO1, CLDN5*) and *MUC2* in the ileal mucosa. Furthermore, avilamycin inclusion used as a positive control in this study also downregulated the expression of tight junction proteins (*ZO1, CLDN5, OCLN*). Reduced gene expression of tight junction proteins and *MUC2* is usually associated with pathogenic challenge and pathological conditions ([@bib11], [@bib56], [@bib55], [@bib2], [@bib5], [@bib27]) that are characterized by severe ileal inflammation ([@bib2], [@bib5]). Generally, the gut is an organ that remains under a physiological state of mild inflammation when exposed to an array of continuous challenges ([@bib39], [@bib38]). However, in this study no sign of abnormal inflammation was present in any of the treatments. The latter could be also supported by the unaffected ileal mucosa IgA levels. Moreover, the fact that the birds from this study had improved zootechnical performance and nutrient digestibility ([@bib40]) could provide further proof for the absence of abnormal inflammation. The downregulated expression of tight junction proteins in AV group could be explained by considering the postulated anti-inflammatory role of avilamycin and other AGP ([@bib10], [@bib36]) in the absence of pathogenic challenges as in this study.

Defense against pathogens and maintenance of homeostasis are dependent on signaling pathways induced by receptors such as toll-like receptors (TLRs). Toll-like receptors sense the presence of conserved microbial structures in the environment and instruct the eukaryotic cells to an adequate response; TLR2 and TLR4 recognize mainly bacterial cell wall components of Gram-positive and Gram-negative bacteria, respectively ([@bib50]). A major signaling target of the TLRs is activation of the transcription factor NF-κB, a key regulator of immune and inflammatory responses ([@bib57]). Organic acids-based formulation inclusion did not affect ileal mucosa *TLR2*, *TLR4* and *NF-κB* expression. A possible explanation for this could be that the OABF inclusion did not also affect the ileal microbiota. Indeed, it is known that most commensal bacteria do not activate or limit NF-kB signaling and that in a healthy gut *TLR* expression profiles remain low and contribute to gut homeostasis ([@bib39], [@bib4]). On the other hand, avilamycin inclusion reduced ileal mucosa *TLR2b*, *TLR4* and *NFKB1* expression. This could be explained by the avilamycin induced reduction of *C. perfringens* subgroup levels shown earlier, and/or to an avilamycin anti-inflammatory effect ([@bib10], [@bib36]), through a bacteria-independent inhibition of TLRs.

At cecal level *IgA* expression was downregulated in treatments OA, OAAV and AV compared with the control. To the best of our knowledge there is no other scientific publication dealing with OABF effects on cecal *IgA* expression. However, it could be the result of an overall better management of the cecal environment. On the other hand, cecal *MUC2* was upregulated by OABF addition. It is known that intestinal microbiota can affect mucin turnover by stimulation of mucin gene expression ([@bib49]). Therefore, the observed upregulation of *MUC2* expression could be linked with the increases in the levels of *C. leptum* and *C. coccoides* subgroups.

5. Conclusions {#sec5}
==============

This study has provided additional evidence that diet supplementation with OABF can positively affect cecal microbiota composition and activity of ileal microbial glycolytic enzymes. The expression of genes associated with gut barrier and health was shown to be mostly modulated in the ileum rather than in the ceca. Synergies of OABF with avilamycin were shown for ileal tight junction proteins and cecal *IgA* gene expression. All the above point to an OABF potential to manipulate the intestinal environment that should however be further assessed under stress challenge conditions.
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[^1]: *GAPDH* = glyceraldehyde 3 phophate dehydrogenase; *MUC2* = mucin 2; *IgA* = immunoglobulin A; *ZO1* = zonula occludens-1; *ZO2* = zonula occludens-2; *CLDN1* = claudin-1; *CLDN5* = claudin-5; *CLDN* = occludin; *NFKB1* = nuclear factor kappa B subunit 1; *TLR2B* = toll-like receptor 2 family member B*; TLR4* = toll-like receptor 4.

[^2]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^3]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^4]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^5]: Pooled standard error of means.

[^6]: ^a,\ b^ Interaction means within the same column differ significantly (*P* ≤ 0.05).

[^7]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^8]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^9]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^10]: Pooled standard error of means.

[^11]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^12]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^13]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^14]: Pooled standard error of means.

[^15]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^16]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^17]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^18]: Pooled standard error of means.

[^19]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^20]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^21]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^22]: Pooled standard error of means.

[^23]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^24]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^25]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^26]: Pooled standard error of means.

[^27]: Total VFA = acetic + propionic + butyric + branched VFA + other VFA.

[^28]: Οther VFA = valeric + caproic + heptanoic.

[^29]: Βranched VFA = isobutyric + isovaleric + isocaproic.

[^30]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^31]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^32]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^33]: Pooled standard error of means.

[^34]: Total VFA = acetic + propionic + butyric + branched VFA + other VFA.

[^35]: Οther VFA = valeric + caproic + heptanoic.

[^36]: Βranched VFA = isobutyric + isovaleric + isocaproic.

[^37]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^38]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^39]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^40]: Pooled standard error of means.

[^41]: *MUC2* = mucin 2; *IgA* = immunoglobulin A; *ZO1* = zonula occludens-1; *ZO2* = zonula occludens-2; *CLDN1* = claudin-1; *CLDN5* = claudin-5; *CLDN* = occludin; *NFKB1* = nuclear factor kappa B subunit 1; *TLR2B* = toll-like receptor 2 family member B*; TLR4* = toll-like receptor 4.

[^42]: ^a,\ b^ Interaction means within the same column differ significantly (*P* ≤ 0.05).

[^43]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^44]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^45]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^46]: Pooled standard error of means.

[^47]: *MUC2* = mucin 2; *IgA* = immunoglobulin A; *ZO1* = zonula occludens-1; *ZO2* = zonula occludens-2; *CLDN1* = claudin-1; *CLDN5* = claudin-5; *CLDN* = occludin; *NFKB1* = nuclear factor kappa B subunit 1; *TLR2B* = toll-like receptor 2 family member B*; TLR4* = toll-like receptor 4.

[^48]: ^a--c^ Interaction means within the same column differ significantly (*P* ≤ 0.05).

[^49]: No: no OABF addition; Yes: addition of 1 g OABF/kg diet.

[^50]: No: no avilamycin addition; Yes: addition of 2.5 mg of avilamycin/kg diet.

[^51]: Interaction means from 8 replicate pens per treatment. Treatments include: control -- no additions (CON), 1 g OABF/kg diet (OA), avilamycin 2.5 mg active components/kg diet (AV) and combination of OA + AV (OAAV).

[^52]: Pooled standard error of means.
